Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Expert Review of Hematology|January 19, 2023
Microsimulation to compare activity-related bleed risks between pharmacokinetic-guided rurioctocog alfa pegol prophylaxis and emicizumabShawn X Sun, Samuel Crawford
Managed Care Interface|December 29, 2007
The Medicare Part D doughnut hole: effect on pharmacy utilizationShawn X Sun, Kwan Y Lee
Health Affairs (Project Hope)|November 6, 2007
The impact of Medicare Part D on prescription drug use by the elderlyFrank R Lichtenberg, Shawn X Sun
American Health & Drug Benefits|September 9, 2016
Benefits of Early Roflumilast Treatment After Hospital or Emergency Department Discharge for a COPD ExacerbationQing Lee, Michelle Mocarski, Shawn X Sun
Journal of Blood Medicine|October 3, 2022
Comparison of Real-World Dose and Consumption for Two Extended Half-Life Recombinant Factor VIII Products for the Treatment of Hemophilia A in the United StatesYanyu Wu, Shawn X Sun, Tao Fan
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 1, 2022
Disease Burden in Patients with von Willebrand Disease Potentially Eligible for Prophylaxis: Post Hoc Analysis of a European Cross-Sectional StudyPing Du, George Morgan, Sarah Brighton, et al.
Managed Care (Langhorne, Pa.)|September 25, 2015
Roflumilast: Who Is Using It and How It Affects Health Care Resource Utilization and CostsRahul Jain, Qian Cai, Shawn X Sun, et al.
Journal of Medical Economics|January 23, 2013
Healthcare utilization and costs among chronic bronchitis patients treated with maintenance medications from a US managed care populationAzza AbuDagga, Shawn X Sun, Hiangkiat Tan, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 17, 2013
Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysisAzza Abudagga, Shawn X Sun, Hiangkiat Tan, et al.
Expert Review of Hematology|August 24, 2022
Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia AShawn X Sun, Andrew Frick, Vinod Balasa, et al.
Pageof 4